Financial Data and Key Metrics Changes - The company ended 2025 with $25.7 million in cash equivalents and short-term investments, managing its operating plan to extend its runway through Q4 2026 [30] Business Line Data and Key Metrics Changes - The CBeyond program has shown a clinically meaningful 3% improvement in weight loss over semaglutide alone at 26 weeks, with a 22.3% mean weight loss in the combination arm over 52 weeks [6][18] - Participants on semaglutide alone regained 38.7% of weight over 13 weeks after stopping therapy, while those on the combination of nimacimab plus semaglutide only regained 17.8% [18] Market Data and Key Metrics Changes - The company is positioning nimacimab as a complementary therapy to GLP-1s, targeting second-line add-on settings for patients who have not achieved their weight loss goals with first-line therapies [20][21] Company Strategy and Development Direction - The company is expanding the CBeyond study to include new intravenous cohorts to rapidly generate safety and pharmacokinetic data at higher exposures [14] - The focus is on developing a co-formulation of nimacimab using Halozyme's ENHANZE technology to facilitate high-volume subcutaneous injections [16] - The company aims to determine the exposure and duration of peripheral CB1 engagement required to produce clinically meaningful efficacy [34] Management's Comments on Operating Environment and Future Outlook - Management emphasized the importance of generating clinical data to support nimacimab's potential in the anti-obesity medicine landscape, particularly in combination with GLP-1s [14][19] - The feedback from the FDA has helped refine the Phase 2b protocol, particularly regarding combination therapy development [17] Other Important Information - The company is advancing its first antibody peptide conjugate program, which aims to combine nimacimab's mechanism of action with a GLP-1 receptor agonist [25][28] Q&A Session Summary Question: Plans to share data from higher dose cohorts and status of formulation work - The company is expanding into the Part C expansion study to generate data on higher exposures and expects updates by Q4 2026 [38][39] - The formulation work with Halozyme is ongoing and expected to be ready for the Phase 2b study [40][41] Question: Concerns about dose levels in the expansion study - Management believes the selected doses are sufficient for the Phase 2b selection, but they are continuing to evaluate higher dosing [48] Question: Profile and goals for the new program - The new program is seen as long-term optionality, with nimacimab remaining the core value driver [52] Question: Importance of peripheral tissues for nimacimab's clinical effect - Adipose tissue and liver are critical for nimacimab's effects, with different profiles expected for monotherapy versus combination therapy [61] Question: Use of IV in the Part C phase of the study - IV is being used for the fastest generation of high exposure PK and safety information, with plans for subcutaneous delivery in Phase IIb [65]

March 10, 2026 2025 Q4 Financial Results & Business Update Nasdaq: SKYE © 2026 Skye Bioscience, Inc. Disclaimer and Important Information for Investors This presentation ("Presentation") has been prepared solely for general information purposes by or on behalf of Skye Bioscience, Inc. (together with its subsidiaries and affiliates, "Skye"). Any discussion of the potential use or expected success of our product candidates is subject to our product candidates being approved by regulatory authorities. Cautiona ...

Summary of BridgeBio's 2026 Conference Call Company Overview - **Company**: BridgeBio (NasdaqGS:BBIO) - **Event**: 2026 Leerink Partners Global Healthcare Conference - **Date**: March 10, 2026 Key Points TTR Market and Attruby Performance - **Patient Growth**: Accelerated from approximately 60 patients per week at launch to over 150 patients per week, indicating strong market acceptance [3][5] - **Market Dynamics**: The growth is attributed to: - Strong clinical data supporting Attruby as the first near-complete stabilizer for TTR [3] - Increased disease awareness and improved diagnosis through AI initiatives [4] - Broader prescriber base, particularly high-volume heart failure clinics [4][5] - **Market Share**: Achieved over 25% share in treatment-naive patients within a year of launch, with a goal of exceeding 30% [5] - **Pricing Stability**: Net pricing for Attruby remains stable, with gross-to-net ratios in the 30%-40% range [6][7] European Market and BEYONTTRA - **Partnership with Bayer**: Successful collaboration for the launch of BEYONTTRA, with over 50% treatment-naive share in Germany due to a single-payer system [9][10] - **Future Launches**: Upcoming launches planned in Denmark, Spain, Italy, and France, with royalties starting at 30% [11] Combination Therapy and Competitive Landscape - **Tafamidis IP Discussion**: Potential outcomes for tafamidis patent litigation could impact market dynamics, with expectations of generic entry possibly in the 2030s [12] - **Combination Therapy Insights**: Current data shows no significant benefits from combination therapies, with a focus on establishing Attruby as the most potent stabilizer [13][14] Pipeline Developments - **Depleter Program**: BridgeBio is developing an in-house depleter to complement Attruby, targeting the removal of monomers that cause cardiomyopathy [15][16][17] - **Achondroplasia Strategy**: Infigratinib is positioned as a superior oral treatment option, with a focus on market expansion through patient switches from injections [18][22][23] - **Global Launch Plans**: International strategy involves a phased approach, starting with Germany, with regulatory filings expected to lag behind U.S. timelines by 3-4 months [27][28] Financial Outlook and Margin Profile - **Cost Management**: R&D expenses are expected to remain flat, while SG&A expenses will increase due to upcoming launches [39] - **Margin Expectations**: Anticipated gross margins for new products could reach 70%-80%, with a significant increase in total operating spend as new products launch [50] Additional Insights - **Equity Stake in GondolaBio**: BridgeBio holds an equity stake in GondolaBio, an early-stage R&D engine, which may be integrated into future strategies [52] This summary encapsulates the critical insights and strategic directions discussed during the conference call, highlighting BridgeBio's growth trajectory, market strategies, and financial outlook.

Core Viewpoint - Veru Inc. has initiated the Phase 2b PLATEAU clinical trial for enobosarm, aimed at enhancing weight loss quality and quantity in older patients with obesity when combined with semaglutide [1][2] Group 1: Clinical Trial Details - The Phase 2b PLATEAU trial is a double-blind, placebo-controlled study involving approximately 200 older patients (age ≥ 65 years) with obesity (BMI ≥ 35) starting semaglutide treatment [3] - The primary efficacy endpoint is the percent change from baseline in total body weight at 68 weeks, with an interim analysis at 34 weeks to assess changes in lean body mass and fat mass [3][6] - Key secondary endpoints include total fat mass, total lean mass, physical function, bone mineral density, and patient-reported outcomes [3] Group 2: Drug Development Strategy - Enobosarm is an oral selective androgen receptor modulator (SARM) being developed to work in conjunction with GLP-1 receptor agonists like semaglutide to maximize fat loss while preserving lean mass and physical function [2][4] - The combination therapy aims to address the weight loss plateau experienced by many patients on current therapies, particularly those with clinical obesity [2][4] - The Phase 2b PLATEAU study builds on previous positive results from the Phase 2 QUALITY clinical study, which demonstrated the efficacy of enobosarm in combination with semaglutide [4][8] Group 3: Expected Outcomes and Timeline - An interim analysis for the PLATEAU trial is expected in the first quarter of 2027, with final topline clinical data anticipated in the fourth quarter of 2027 [1][6] - The trial aims to provide critical clinical information that will inform the design of future Phase 3 studies for combination therapies [2][3]

Summary of Madrigal Pharmaceuticals FY Conference Call Company Overview - **Company**: Madrigal Pharmaceuticals (NasdaqGS:MDGL) - **Key Product**: Rezdiffra, a treatment for metabolic-associated steatotic liver disease (MASH) Key Points Revenue Growth and Market Performance - Rezdiffra is annualizing at **$1.3 billion** in its 7th quarter of launch, with the market growing at approximately **50%** over two years [2][19] - The company reported **over 36,250 patients** on therapy, with expectations to close the year with nearly **$1 billion** in sales for 2025 [6][5] - The market penetration is currently at **less than 12%** of the diagnosed patient population, indicating significant growth potential [36] Pipeline Development - Madrigal has expanded its pipeline from a single product to over **10 products** in development, focusing on combination therapies to enhance patient response [11][9] - The company is exploring combination therapies with an oral GLP-1 and siRNA programs targeting MASH, which are expected to improve treatment efficacy [15][17] Financial Outlook - The consensus revenue expectation for 2026 is **$1.48 billion**, reflecting a **50%** increase from 2025 [19] - The company is confident in achieving this target, citing strong momentum from Q4 2025 into 2026 [20] - Gross-to-net pricing is expected to stabilize in the **high 30s** percentage range for 2026, with most commercial contracts already in place [58][39] Risks and Mitigation Strategies - Madrigal acknowledges potential risks from competition, particularly from GLP-1 therapies, but believes that Rezdiffra's unique profile will mitigate these risks [35][36] - The company is actively managing commercial contracting and has secured first-line access without step-through requirements for competing products [44][39] International Market Considerations - The company is in the early stages of launching in Europe, with expectations for significant contributions to revenue growth in the **3-5 year** range [122][123] - Discussions regarding health technology assessments (HTA) and pricing strategies are ongoing, with a focus on establishing a cost-effective position in the European market [132][134] Clinical Trials and Future Studies - The F4C trial is expected to read out in **2027**, with the potential to double the market opportunity for Rezdiffra if successful [206][212] - The company is focused on retaining patients in ongoing studies to ensure sufficient event data for regulatory approval [204][205] Combination Therapy Development - Madrigal is developing a combination therapy with ervogastat, a DGAT2 inhibitor, which is expected to enhance the efficacy of Rezdiffra [223][226] - The oral GLP-1 program (MGL-2086) is also in development, with plans to start clinical trials in **2027** [244][243] Conclusion - Madrigal Pharmaceuticals is positioned for significant growth with a strong product pipeline and a focus on expanding market share in the MASH treatment space. The company is actively managing risks and preparing for future clinical trials that could enhance its market position.

Delcath Systems (NasdaqCM:DCTH) Q4 2025 Earnings call February 26, 2026 08:30 AM ET Company ParticipantsBill Maughan - Managing DirectorCharles Wallace - Managing DirectorDavid Hoffman - General Counsel, Corporate Secretary and CCOGerard Michel - CEOJohn Newman - Managing DirectorSandra Pennell - CFOSudan Loganathan - Managing DirectorConference Call ParticipantsChase Knickerbocker - Senior Research AnalystMarie Thibault - Managing Director and Medical Technology and Digital Health AnalystYale Jen - Senior ...

Summary of Madrigal Pharmaceuticals FY Conference Call Company Overview - **Company**: Madrigal Pharmaceuticals (NasdaqGS:MDGL) - **Industry**: Metabolic and liver disease - **Key Product**: Rezdiffra, the first-ever approved product for MASH (Metabolic Associated Steatotic Hepatitis) Core Points and Arguments 1. **Market Leadership**: Madrigal is positioned as a leader in the MASH space with a successful product launch, achieving over $1 billion in annualized sales after six quarters [3][4][29]. 2. **Future Growth**: The company anticipates significant growth opportunities with the upcoming F4C indication data expected in 2027, which could potentially double the market opportunity for Rezdiffra [4][30]. 3. **Patient Base**: As of Q3 2025, over 29,500 patients are on Rezdiffra therapy, with 10,000 prescribers, indicating a strong foundation for continued growth [9][10]. 4. **Market Dynamics**: The MASH market is currently under-penetrated, with only 10% of diagnosed patients being treated. The company sees potential for expansion similar to other large specialty markets [11][12]. 5. **Pipeline Development**: Madrigal is focused on building a robust pipeline in MASH, including new mechanisms of action and combination therapies to enhance treatment efficacy [17][18][20]. Important Developments 1. **Combination Therapies**: The company is exploring combination therapies with new assets like a DGAT2 inhibitor and an oral GLP-1 molecule, which are expected to enhance the efficacy of Rezdiffra [20][25]. 2. **Clinical Trials**: Ongoing and upcoming trials include the Maestro Outcomes trial for F4C and the Maestro NASH study for F2, F3, with data expected in 2027 and 2028 respectively [17][18]. 3. **Market Access**: Madrigal has secured first-line access with no step-edit requirements, which is crucial for maintaining strong market presence against competitors [10][49]. Financial Outlook 1. **Sales Growth**: The company expects robust net revenue growth in 2026 despite anticipated changes in gross-to-net dynamics due to commercial contracting [49][50]. 2. **Profitability Timeline**: While profitability is not the immediate focus, the company is confident in achieving it as top-line growth outpaces spending [45][46]. Additional Insights 1. **Global Expansion**: Madrigal has launched in Germany and is exploring opportunities in other countries, particularly in the Middle East, but does not expect significant contributions from international sales in 2026 [55][56]. 2. **Competitive Landscape**: The company acknowledges the presence of competitors but believes that the unique profile of Rezdiffra and its established market access will allow it to thrive [10][53]. Conclusion Madrigal Pharmaceuticals is strategically positioned to lead the MASH market with its innovative product Rezdiffra and a growing pipeline. The company is focused on maximizing its market potential through combination therapies and expanding its patient base while maintaining a strong financial outlook for the coming years [28][30].

Core Insights - Amplia Therapeutics Limited has entered the second phase of a research collaboration with Next & Bio to further investigate the efficacy of its FAK inhibitors in treating pancreatic cancer [2][3][4] - The collaboration aims to explore the synergistic effects of Amplia's FAK inhibitor narmafotinib in combination with kRAS inhibitors, which target genetic mutations present in over 90% of pancreatic cancers [3][4][9] - Initial studies have shown that narmafotinib demonstrated promising activity against patient-derived pancreatic cancer cells, with plans to present this data at an upcoming scientific conference [3][6] Company Overview - Amplia Therapeutics is an Australian pharmaceutical company focused on developing a pipeline of FAK inhibitors for cancer and fibrosis, particularly in fibrotic cancers like pancreatic and ovarian cancer [7] - Narmafotinib (AMP945) is Amplia's leading FAK inhibitor, which has shown significant potential in preclinical studies and is currently undergoing clinical trials in combination with established chemotherapies [8][10] Collaboration Details - The partnership with Next & Bio, a preclinical drug screening company, leverages patient-derived cell models to provide more accurate and predictive results for pancreatic cancer treatment [5][6] - The collaboration is expected to enhance Amplia's strategic positioning for future partnerships and commercial growth opportunities [6]

Core Insights - Aligos Therapeutics, Inc. announced positive data from four presentations at the HEP-DART 2025 Meeting, showcasing advancements in therapies for liver and viral diseases [1][2] Pevifoscorvir Sodium Data - The Phase 1 monotherapy study of pevifoscorvir sodium for chronic hepatitis B virus (HBV) infection demonstrated its potential as a first-line therapy, with complete 96-week and post-treatment follow-up data indicating continued efficacy [3][6] ALG-055009 Data - New in vivo data from studies on diet-induced obese mice showed that the combination of ALG-055009 with incretin receptor agonists resulted in significant weight loss, with SEMA monotherapy achieving a maximum of 23.9% body weight loss, while the combination with ALG-055009 led to an additional 8.6% decrease for a total of 33% [4][5] - TIRZEP monotherapy resulted in a maximum of 27.1% and 34.4% body weight loss for low and high doses respectively, with combinations yielding up to 40% weight loss [4][5] Synergistic Effects - The combination therapy of ALG-055009 with incretin receptor agonists primarily resulted in fat mass loss without significantly affecting lean mass or food consumption, indicating a beneficial addition to existing therapies for weight loss [5][6] Future Directions - The company expressed enthusiasm for the potential of both pevifoscorvir sodium and ALG-055009, highlighting their commitment to advancing next-generation therapies for chronic HBV and metabolic diseases [6][9]

Core Insights - GENFIT reports encouraging preliminary Phase 1b data for GNS561 in combination with a MEK inhibitor for treating advanced KRAS mutated cholangiocarcinoma (CCA) [1][6] Clinical Trial Context and Objective - CCA is a rare and aggressive bile duct cancer with limited treatment options and poor prognosis [2] - GNS561 is an investigational small molecule targeting PPT1, aiming to inhibit autophagy and promote cancer cell death [2] - The ongoing Phase 1b study evaluates the safety and tolerability of GNS561 combined with trametinib, a MEK inhibitor, in patients who have failed prior therapies [2] Preliminary Results - The analysis included 9 patients, with 4 reaching tumor assessment at week 6, showing disease control and tumor reduction [3][6] - Disease stabilization was observed in all evaluated patients, with tumor shrinkage noted in a subgroup [7] Clinical Impact - The combination of GNS561 and MEK inhibitors shows potential to address critical unmet medical needs in oncology, particularly for patients with advanced solid tumors [4] - The consistent disease stabilization and tumor shrinkage suggest meaningful clinical benefits, warranting further investigation [4] Next Development Steps - Phase 1b dose escalation will continue, with new data expected in Q1 2026 to establish recommended Phase 2 doses [8] - Phase 2 initiation is targeted for the second half of 2026 [8] About GNS561 - GNS561 is a first-in-class investigational agent with a novel mechanism of action, developed for advanced solid tumors [10] - GENFIT acquired full intellectual property rights for GNS561 in early 2025, expanding its development capabilities [10] About GENFIT - GENFIT is a biopharmaceutical company focused on rare, life-threatening liver diseases, with a history of over two decades in liver disease research [12] - The company has a diverse R&D portfolio, including therapies for cholangiocarcinoma and other serious diseases [12]